Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase IIa, randomized, blinded, placebo controlled,Multiple-Ascending Dose study of BBT001 in adult patients with Chronic Spontaneous Urticaria.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-16.
Trial Details
NCT Number NCT07717905
Lead Sponsor Bambusa Therapeutics
Conditions Chronic Spontaneous Urticaria
Enrollment 48 participants
Start Date 2026-06-29
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22